Byondis
Declan Nolan is a seasoned professional with extensive experience in strategic business initiatives within the biopharmaceutical sector. Currently serving as Director of Strategic Business Initiatives at Byondis since April 2020, Declan previously held various senior roles at Synthon Biopharmaceuticals B.V. from 2002 to April 2020, including Vice President of Strategic Business Initiatives and Strategic Program Development Manager. Earlier career experience includes a postdoctoral position at Radboud University Nijmegen from 2000 to 2002. Declan holds an MSc in Applied Toxicology from the University of Surrey, a PhD in Animal Physiology from Radboud University, a BSc (Hons) in Zoology from University College Dublin, and several qualifications from the College of Marketing & Design.
This person is not in the org chart
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.